Figure 4:

Distribution of methylation-based subclasses. (A) Comparison of DNA methylation data according to MNP12.5 of the GC cohort (n = 40) and the published population-based collective by Sturm et al.²² (n = 80). The subclasses were arranged based on the WHO CNS 2021 classification. In the cohort by Sturm et al., only supratentorial cases with hemispheric location were included. All non-diffuse glioma subclasses, isolated midline location, and with a calibrated score <0.9 were excluded. Infant-type H3-wild-type tumors were not considered in the analysis to approximate the age distribution between the 2 cohorts (median 12 years [1–21] vs. 11.8 years [1.3–18.8]). In the category “others” 22 tumors of “pleomorphic xanthoastrocytoma (-like)” and 2 tumors of the subclass “neuroepithelial tumor, PLAGL1-fused” were present. There was an overlap between these 2 collectives as 2 cases occurred in both the here-reported GC and the control cohort. Therefore, in the subclasses pedHGG_A/B and pedHGG_RTK2A/B, 1 patient is listed once in each of the 2 cohorts. Of note, the only pedHGG_A/B-case in the reference collective was a child from the here-presented GC cohort. (B) Relative frequencies of different subclasses in the diffuse pediatric-type high-grade glioma, H3-wild-type, and IDH-wild-type subgroup of the 2 above-mentioned cohorts. *There was a significant difference in the frequencies of pedHGG_RTK2A/B- and pedHGG_RTK1A/B/C subclasses between the 2 cohorts.